- Design
- Network meta-analysis of 5 randomised placebo-controlled trials
- Population
- 4,227 adults with hypercholesterolaemia
- Primary outcome
- Percentage change in LDL cholesterol from baseline
- Effect
- Up to -61.8 percentage points (95% CI -78.1 to -45.5) vs placebo; certainty low
A network meta-analysis pooled five randomised placebo-controlled trials (4,227 participants) of three orally taken PCSK9 inhibitors, two peptides and one small molecule, treating each drug and dose separately.
Every dose lowered LDL cholesterol. The largest reductions were around 59 to 62 percentage points against placebo for the higher doses of NNC0385-0434 and MK-0616. Higher doses worked better within each drug, but the top-ranked doses could not be told apart, and almost all comparisons between drugs were indirect. No short-term safety signal emerged. Certainty was rated low.
An oral option could reach patients for whom injections, cold storage or cost have kept PCSK9 inhibition out of reach, a real issue in India. But these are lipid results over months. There are no cardiovascular outcome data yet, and none of these agents is approved by CDSCO.
- Oral PCSK9 inhibitors lower LDL cholesterol by a similar magnitude to injectable ones in short trials.
- No outcome trial has yet reported, and these drugs are not available in India.
- Statin plus ezetimibe remains the first step for patients above their LDL goal.
- Ranking one oral agent above another is not supported by the current data.
Why it matters
Route and storage, not efficacy, have limited PCSK9 inhibition, and an oral form would remove both barriers.
Don't overread it
LDL lowering is a surrogate; no trial has yet shown fewer heart attacks or deaths with an oral PCSK9 inhibitor.
The statistics, in plain English
The reductions are percentage points of LDL change against placebo, so -60 means a drop about 60 points larger than placebo's. An I-squared of 80.6% looked worrying but fell to 0% when trials were compared at the same week 24 timepoint, so the variation came from timing rather than the drugs.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free